Compounds > 3',4',5'-trimethoxyflavonol
Page last updated: 2024-12-09

3',4',5'-trimethoxyflavonol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3',4',5'-trimethoxyflavonol: has anticarcinogenic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID688827
CHEMBL ID1999102
SCHEMBL ID4649257
MeSH IDM0581646

Synonyms (10)

Synonym
3',5'-trimethoxy-3-hydroxy flavone
3',4',5'-trimethoxyflavonol
CHEMBL1999102
3-hydroxy-3',4',5'-trimethoxyflavone
SCHEMBL4649257
AKOS024285577
4h-1-benzopyran-4-one, 3-hydroxy-2-(3,4,5-trimethoxyphenyl)-
MWFLTXAQDCOKEK-UHFFFAOYSA-N
3-hydroxy-3',4',5'-trimethoxyflavone, aldrichcpr
Q63409789

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, quercetin's low solubility and poor bioavailability have restricted its applicability; as a result, researchers have attempted to design and synthesize numerous novel quercetin derivatives using various methodologies in order to modify quercetin's constraints; the physico-chemical properties of quercetin's molecular scaffold make it appealing for drug development; low molecular mass and chemical groups are two of these characteristics."( Quercetin derivatives: Drug design, development, and biological activities, a review.
Alizadeh, SR; Ebrahimzadeh, MA, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID1871938Anticancer activity against human HCT-116 cells xenografted in mouse assessed as fold decrease in tumor growth measured after 3 weeks by digital caliper method2022European journal of medicinal chemistry, Feb-05, Volume: 229Quercetin derivatives: Drug design, development, and biological activities, a review.
AID1462065Cell cycle arrest in human PC3 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 37.5%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462060Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462076Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 1 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462081Induction of apoptosis in human PC3 cells assessed as viable cells at 10 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462061Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462086Induction of apoptosis in human PC3 cells assessed as necrotic cells at 20 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462066Cell cycle arrest in human PC3 cells assessed as accumulation at G0/G1 phase at 20 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 37.5%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462097Cmax in C57BL/6J mouse prostate at 240 mg/kg, po administered as single dose measured after 6 hrs post administration2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462079Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 5 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462071Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase at 10 uM after 16 hrs by propidium iodide staining-based flow cytometry (Rvb = 32.3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462062Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462083Induction of apoptosis in human PC3 cells assessed as necrotic cells at 10 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462070Cell cycle arrest in human PC3 cells assessed as accumulation at S phase at 20 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 8.0%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462087Induction of apoptosis in human PC3 cells assessed as viable cells at 30 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462068Cell cycle arrest in human PC3 cells assessed as accumulation at S phase at 20 uM after 16 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.9%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462059Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1871920Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition by Z2 coulter counter based analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Quercetin derivatives: Drug design, development, and biological activities, a review.
AID1462085Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 20 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462063Cell cycle arrest in human PC3 cells assessed as accumulation at G0/G1 phase at 10 uM after 16 hrs by propidium iodide staining-based flow cytometry (Rvb = 34.1%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID671218Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1462095Induction of apoptosis in human PC3 cells assessed as necrotic cells at 100 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1871937Anticancer activity against ApcMin harboring mouse model assessed as fold increase in p53 expression measured after 16 weeks by digital caliper method2022European journal of medicinal chemistry, Feb-05, Volume: 229Quercetin derivatives: Drug design, development, and biological activities, a review.
AID1462096Induction of apoptosis in human PC3 cells assessed as apoptotic cells after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462088Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 30 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462064Cell cycle arrest in human PC3 cells assessed as accumulation at G0/G1 phase at 20 uM after 16 hrs by propidium iodide staining-based flow cytometry (Rvb = 34.1%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462069Cell cycle arrest in human PC3 cells assessed as accumulation at S phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 8.0%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462080Induction of apoptosis in human PC3 cells assessed as necrotic cells at 5 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462067Cell cycle arrest in human PC3 cells assessed as accumulation at S phase at 10 uM after 16 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.9%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID671217Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID759072Cytotoxicity against human HCT116 cells assessed as cell viability at 15 uM after 48 hrs by MTT assay relative to control2013European journal of medicinal chemistry, Jul, Volume: 65Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin.
AID1462084Induction of apoptosis in human PC3 cells assessed as viable cells at 20 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID671219Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1462094Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 100 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1183093Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis and effects on cell viability of flavonols and 3-methyl ether derivatives on human leukemia cells.
AID1462075Induction of apoptosis in human PC3 cells assessed as viable cells at 1 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462089Induction of apoptosis in human PC3 cells assessed as necrotic cells at 30 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462091Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 50 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462092Induction of apoptosis in human PC3 cells assessed as necrotic cells at 50 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID671220Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID671213Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1462082Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 10 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462073Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 27.8%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462093Induction of apoptosis in human PC3 cells assessed as viable cells at 100 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462090Induction of apoptosis in human PC3 cells assessed as viable cells at 50 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462077Induction of apoptosis in human PC3 cells assessed as necrotic cells at 1 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 2 to 3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462078Induction of apoptosis in human PC3 cells assessed as viable cells at 5 uM after 16 hrs by F2N12S and CYTOX AADvanced double staining-based flow cytometric analysis (Rvb = 95%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462072Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase at 20 uM after 16 hrs by propidium iodide staining-based flow cytometry (Rvb = 32.3%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1462074Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase at 20 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 27.8%)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-hydroxyflavone
3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.		3.1950flavonols;
monohydroxyflavone
etoposide
[no description available]		2.110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
3,5,7,3',4'-pentamethoxyflavone
3,5,7,3',4'-pentamethoxyflavone: causes relaxation of cavernosum; structure in first source		3.5110
3',4',5'-trimethoxyflavone
3',4',5'-trimethoxyflavone: structure in first source		2.0710ether;
flavonoids
2'-hydroxychalcone
2'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'.		2.0810chalcones;
phenols		anti-inflammatory agent
quercetin
[no description available]		4.32507-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
luteolin
[no description available]		3.51103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
quercetin 3-o-glucopyranoside
quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells		3.5110beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		3.5110disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
kaempferol
[no description available]		2.07107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
3,7,4'-trihydroxyflavone
3,7,4'-trihydroxyflavone: structure in first source		2.0710hydroxyflavan
fisetin
[no description available]		2.51203'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
galangin
5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.		3.51107-hydroxyflavonol;
trihydroxyflavone		antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite
myricetin
[no description available]		2.07107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
robinetin
robinetin: structure given in first source. robinetin : A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 7, 3, 4' and 5'.		2.07107-hydroxyflavonol;
pentahydroxyflavone		plant metabolite
2'-hydroxy-4-methoxychalcone
[no description available]		2.0810
5-hydroxy-3,3',4',7-tetramethoxyflavone
5-hydroxy-3,7,3',4'-tetramethoxyflavone: from the rhizome of Kaempferia parviflora; inhibits monocyte adhesion and cellular reactive oxygen species production in human umbilical vein endothelial cells. 5-hydroxy-3,3',4',7-tetramethoxyflavone : A monohydroxyflavone that is 5-hydroxyflavone which is substituted by methoxy groups at positions 3,3',4' and 7.		2.1103'-methoxyflavones;
monohydroxyflavone;
tetramethoxyflavone		plant metabolite
Crotaoprostrin
[no description available]		2.0810chalcones
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.830
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.830
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0710